ARRIVENT BIOPHARMA, INC. (AVBP) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $864.96M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-267.00K; Retained Earnings (Accumulated Deficit)USD $-497.85M.
- 2026-03-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $772.21M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-270.00K; Retained Earnings (Accumulated Deficit)USD $-447.96M.
- 2025-12-31: Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $711.85M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $14.00K; Retained Earnings (Accumulated Deficit)USD $-404.64M.
- 2025-09-30: Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $673.88M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $206.00K; Retained Earnings (Accumulated Deficit)USD $-369.10M.
ARRIVENT BIOPHARMA, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Outstanding USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00K | $864.96M | $-267.00K | $-497.85M | $366.84M | 3 month · $2.51M | 3 month · $6.67M | (m) |
| 2026-03-31 | $5.00K | $772.21M | $-270.00K | $-447.96M | $323.98M | 3 month · $2.42M | 3 month · $5.49M | (m) |
| 2025-12-31 | $4.00K | $711.85M | $14.00K | $-404.64M | $307.22M | 12 month · $10.67M | 12 month · $12.52M | (m) |
| 2025-09-30 | $4.00K | $673.88M | $206.00K | $-369.10M | $305.00M | 3 month · $5.83M | 3 month · $3.72M | (m) |
| 2025-06-30 | $4.00K | $584.00M | $-18.00K | $-334.12M | $249.87M | 3 month · $2.40M | 3 month · $3.31M | (m) |
| 2025-03-31 | $4.00K | $505.27M | $-17.00K | $-302.72M | $202.54M | 3 month · $858.00K | 3 month · $2.27M | (m) |
| 2024-12-31 | $3.00K | $496.19M | $-211.00K | $-238.33M | $257.65M | 12 month · $18.03M | 12 month · $3.21M | (m) |
| 2024-09-30 | $3.00K | $495.19M | (m) | $-217.70M | $277.49M | (m) | 3 month · $866.00K | (m) |
| 2024-06-30 | $3.00K | $493.79M | (m) | $-197.14M | $296.66M | (m) | 3 month · $766.00K | (m) |
| 2024-03-31 | $3.00K | $492.98M | (m) | $-175.26M | $317.72M | 3 month · $18.03M | 3 month · $625.00K | $0.00 |
| 2023-12-31 | (m) | $4.65M | (m) | $-157.84M | $-153.19M | (m) | 12 month · $895.00K | $0.00 |
| 2023-09-30 | (m) | (m) | (m) | (m) | $-132.60M | (m) | 3 month · $217.00K | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | $-118.46M | (m) | 3 month · $193.00K | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | $-97.09M | (m) | 3 month · $166.00K | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | $-85.11M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |